Trial
NCT04944173
SCION: SABR and Checkpoint Inhibition of NSCLC
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of British Columbia
Collaborators
AstraZeneca; Ozmosis Research Inc.
Condition
Non Small Cell Lung Cancer
Intervention
Durvalumab
Why stopped
Overestimated pool of eligible patients and the potential participants either declined participation or did not meet eligibility criteria.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-03